Wellesley, MA, United States of America

Ana Maria Carrion

USPTO Granted Patents = 1 

Average Co-Inventor Count = 17.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2022

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovator Spotlight: Ana Maria Carrion from Wellesley, MA

Introduction

Ana Maria Carrion is a distinguished inventor based in Wellesley, Massachusetts. With her pioneering work in the biotechnology sector, she continues to make significant contributions to the field of medical research. Her innovative approach has positioned her as a notable figure in the development of therapeutic antibodies.

Latest Patents

Ana Maria holds one patent titled "Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules." This patent provides essential information on anti-BTC antibodies, alongside methods for producing these antibodies and pharmaceutical compositions containing them. Furthermore, it features multi-specific binding molecules, including bispecific antibodies, which combine a BTC binding moiety and an anti-VEGF binding moiety. This groundbreaking work showcases her dedication to advancing medical treatments.

Career Highlights

Ana Maria Carrion's career has been marked by her tenure at Novartis AG, a leading global healthcare company dedicated to reimagining medicine. Throughout her career, she has not only engaged in high-impact research but has also contributed to the development of innovative therapies that enhance patient care.

Collaborations

In her journey, Ana Maria has collaborated with other talented professionals, including colleagues Chad Eric Bigelow and James Edgar Chastain. These collaborations reflect a collective effort to harness diverse expertise and drive forward the frontiers of biomedical science.

Conclusion

Ana Maria Carrion exemplifies the spirit of innovation in the field of biotechnology. Her patent work on anti-BTC antibodies is a testament to her commitment to improving healthcare outcomes. As she continues to work at Novartis AG and collaborates with fellow researchers, her contributions are poised to leave a lasting impact on the medical community.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…